文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

玻璃体腔注射康柏西普与雷珠单抗治疗早产儿视网膜病变的短期结局比较

SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.
PubMed 文献 · Retina · 2018-01-01

本文回顾性连续病例系列比较玻璃体腔注射康柏西普(IVC)与雷珠单抗(IVR)治疗早产儿视网膜病变(ROP)的結構结局与复发情况。共纳入48眼(24例),IVC组20眼、IVR组28眼,主要结局为附加病变消退。两组均有效,IVC组85%仅需一次注射,IVR组53.6%需二次注射,两组均未观察到视网膜脱离。

要点

  • IVC组20眼中17眼(85%)仅需一次注射,附加病变平均4.3±2.08周后消退。
  • IVR组28眼中15眼(53.6%)接受第二次注射,其中10眼为复发、5眼为一次注射未愈。
  • 两组均未观察到视网膜脱离,康柏西普与雷珠单抗均为ROP的有效治疗选择。

核心结论

  • 康柏西普与雷珠单抗均为早产儿视网膜病变的有效治疗选择,康柏西普为眼科医生提供了一种新的治疗选择。

研究设计与样本

  • 回顾性连续病例系列,纳入接受玻璃体腔注射康柏西普(IVC)或雷珠单抗(IVR)治疗的早产儿视网膜病变患眼共48眼(24例)。
  • IVC组20眼(10例),IVR组28眼(14例);主要结局为附加病变消退,次要结局为附加病变复发、注射次数及最终病变消退。

主要发现

  • IVC组20眼中18眼为II区3+期ROP、2眼为侵袭性后极部ROP;IVR组28眼中6眼为I区2/3+期ROP、6眼为侵袭性后极部ROP、16眼为II区3+期ROP。
  • IVC组患儿平均出生胎龄29.49±1.37周、出生体重1369.0±161.9 g、首次治疗时矫正胎龄38.47±2.72周、随访52.6±21.4周;IVR组分别为28.35±1.62周、1171.4±279.9 g、38.53±3.54周、42.9±9.8周。
  • IVC组20眼中17眼(85%)仅接受一次注射,附加病变于4.3±2.08周后消退;3眼(15%)一次注射未愈后接受第二次IVC,附加病变于3周内消退。
  • IVR组28眼中15眼(53.6%)接受第二次IVR,其中10眼为复发、5眼为一次注射未愈。
  • 两组均未观察到视网膜脱离。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intravitreal injection of conbercept (IVC) is the latest applied treatment that could be used in retinopathy of prematurity (ROP) patients. The structural outcomes and recurrence of ROP among patients treated with IVC or intravitreal injection of ranibizumab (IVR) were compared. METHODS: A consecutive case series of ROP treated with IVC or IVR were retrospectively studied. The primary outcome was treatment success defined as regression of plus disease. The secondary outcomes were recurrence of plus, times of injection, and the final regression of disease. RESULTS: A total of 48 eyes (24 patients) with ROP were included. Twenty eyes (10 patients) received IVC, and 28 eyes (14 patients) received IVR. For the IVC group, 18 eyes had Zone II 3+ ROP and 2 eyes had aggressive posterior ROP. Among the 28 eyes treated with IVR, 6 eyes had Zone I 2/3+ ROP, 6 eyes had aggressive posterior ROP, and 16 eyes had Zone II 3+ ROP. For the IVC group, the mean gestational age, birth weight, postmenstrual age at initial treatment, and follow-up period for the infants were 29.49 ± 1.37 weeks, 1,369.0 ± 161.9 g, 38.47 ± 2.72 weeks, and 52.6 ± 21.4 weeks, respectively. And for the infants who received IVR, these were 28.35 ± 1.62 weeks, 1,171.4 ± 279.9 g, 38.53 ± 3.54 weeks, and 42.9 ± 9.8 weeks, respectively. For the IVC group, 17 (85%) of 20 eyes received the injection only once, and the regression of plus disease occurred 4.3 ± 2.08 weeks later. Three eyes (15%) did not healed with one injection received a second IVC, and the regression of plus disease occurred within 3 weeks. For the IVR group, 15/28 (53.6%) eyes received a second IVR. Among them, 10 recurrent eyes and 5 eyes did not recover with one injection. No retinal detachment was observed in both group infants. CONCLUSION: Both conbercept and ranibizumab are effective choice for the treatment of ROP. Conbercept is a novel effective treatment strategy for ROP providing a new treatment option for ophthalmologists.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Jin E, Yin H, Li X, et al. SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY. Retina. 2018. PMID: 28699927. doi:10.1097/IAE.0000000000001763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。